UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
_____________

FORM 8-K
_____________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  November 9, 2009

Keryx Biopharmaceuticals, Inc.
 (Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)
000-30929
 (Commission File Number)
 
13-4087132
 (IRS Employer Identification
No.)

750 Lexington Avenue
New York, New York 10022
 (Address of Principal Executive Offices)

(212) 531-5965
 (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 
£
Written communications pursuant to Rule 425 under the Securities Act.
 
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
 
£
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
 
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
 
 
 
 

Item 2.02 Results of Operations and Financial Condition.
 
On November 9, 2009, Keryx Biopharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations for the third quarter ended September 30, 2009.  The Company also announced that on Tuesday, November 10, 2009, at 8:30am EST, the Company will host an investor conference call during which the Company will provide a brief financial overview of the third quarter 2009 financial results and a business outlook for the remainder of 2009. A copy of the press release is being furnished as Exhibit 99.1 to this report.

 
- 2 -
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Keryx Biopharmaceuticals, Inc.
 
(Registrant)
     
Date:  November 9, 2009
    
     
 
By:
 /s/ James F. Oliviero
   
   
Chief Financial Officer
 
 
- 3 -
 

INDEX TO EXHIBITS

Exhibit
    
Number
  
Description
     
99.1
  
Press Release dated November 9, 2009

 
- 4 -